Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Paul Kelsen, MD
Memorial Sloan Kettering Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cancer Center of Southern Alabama
Mobile, Alabama, United States
- Loma Linda University Medical Center
Loma Linda, California, United States
- Veterans Affairs Medical Center - San Francisco
San Francisco, California, United States
- Veterans Affairs Medical Center - Washington, Dc
Washington D.C., District of Columbia, United States
- Florida Cancer Specialists
Fort Myers, Florida, United States
- Savannah Hematology Oncology Associates
Savannah, Georgia, United States
- Northwest Medical Specialists, P.C.
Arlington Heights, Illinois, United States
- Michiana Hematology/oncology P.C.
South Bend, Indiana, United States
- Siouxland Hematology-Oncology
Sioux City, Iowa, United States
- Louisiana Oncology Associates
Lafayette, Louisiana, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Memorial Hospital
Worcester, Massachusetts, United States
- Missoula Medical Oncology P.C.
Missoula, Montana, United States
- Nevada Cancer Center
Las Vegas, Nevada, United States
- University of Medicine and Dentistry of New Jersey - Mobile
Newark, New Jersey, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Nyu School of Medicine'S Kaplan Comprehensive Cancer Center
New York, New York, United States
- Rochester General Hospital
Rochester, New York, United States
- Albert Einstein Comprehensive Cancer Center
The Bronx, New York, United States
- New York Medical College
Valhalla, New York, United States
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States
- Pitt County Memorial Hospital
Greenville, North Carolina, United States
- Akron City Hospital
Akron, Ohio, United States
- Hollings Cancer Center
Charleston, South Carolina, United States
- Palmetto Hematology/oncology Associates
Spartanburg, South Carolina, United States
- Harrington Cancer Center
Amarillo, Texas, United States
- Lone Star Oncology
Austin, Texas, United States
- Oncology Consultants
Houston, Texas, United States
- University of Texas - Md Anderson Cancer Center
Houston, Texas, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 1997
- Primary completion
- —
- Completion
- —
- Last update posted
- 24 Jul 2008
- Registered enrollment
- 100
- Registry id
- NCT00003326
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.